Quote | Orphazyme A/S (NASDAQ:ORPH)
Last: | $0.87 |
---|---|
Change Percent: | -2.25% |
Open: | $0.906 |
Close: | $0.87 |
High: | $0.9571 |
Low: | $0.8457 |
Volume: | 763,915 |
Last Trade Date Time: | 03/30/2022 04:55:01 pm |
News | Orphazyme A/S (NASDAQ:ORPH)
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...
Message Board Posts | Orphazyme A/S (NASDAQ:ORPH)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Orphazyme A/S Company Name:
ORPH Stock Symbol:
NASDAQ Market:
(NewsDirect) hVIVO chairman Cathal Friel joined Proactive's Stephen Gunnion to discuss the sale of shares in hVIVO PLC by directors, including himself. Friel explained his decision to sell a portion of his shares in hVIVO was to accommodate the high demand from major institutions whil...
(NewsDirect) hVIVO PLC (AIM:HVO) Chief Scientific Officer Andrew Catchpole speaks to Steve Darling from Proactive after the specialist contract research organisation announced it has secured a £6.3 million contract with a biotechnology client for the testing of their antiviral candid...
(NewsDirect) hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after the specialist contract research organisation announced it has signed a £16.8mln full-service human challenge contract with a top-five global pharmaceutical company. Khan explain...